GSK plc (GSK,GSK.L) said that the China National Medical Products Administration has approved Nucala or mepolizumab as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.
Nucala is the first anti-Interleukin-5 (IL-5) targeting treatment approved for use in China for adult and adolescent patients with this condition.
The approval was based on a separate Phase III trial among Chinese patients, reinforcing the efficacy and safety data of mepolizumab.
This is the second indication for mepolizumab in China, with approval for use in adults with eosinophilic granulomatosis with polyangiitis or EGPA received in 2021. Epidemiological, clinical and pathophysiological studies show that patients with EGPA usually also have asthma, which is often severe.
Asthma is a major health burden in China affecting an estimated 46 million adults. In China, 15.5% of people with asthma have experienced an exacerbation requiring a hospital visit in the preceding 12 months.
For More Such Health News, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.